Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
ACS Medicinal Chemistry Letters|December 20, 2023
The Promiscuity of Disulfiram in Medicinal ResearchBoris Cvek
RSC Advances|July 10, 2026
Comment on "Disulfiram as an anti-inflammatory agent: mechanisms, nano-delivery strategies, and applications in non-oncologic diseases" by Q. Jiang, M. Jiang, Y. Lv, X. Zhang, S. Wang and J. Zhao, <i>RSC Adv.</i>, 2025, <b>15</b>, 36344Boris Cvek
Drug Discovery Today|June 6, 2022
Multiple deadlocks in the development of nonprofit drugsBoris Cvek
Drug Discovery Today|December 24, 2011
Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)Boris Cvek
Progress in Molecular Biology and Translational Science|June 26, 2012
Proteasome inhibitorsBoris Cvek
Drug Discovery Today|June 27, 2008
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?Boris Cvek, Zdenek Dvorak
Critical Reviews in Oncology/Hematology|June 4, 2014
Linking the activity of bortezomib in multiple myeloma and autoimmune diseasesZdeněk Škrott, Boris Cvek
Current Pharmaceutical Design|April 21, 2011
The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomibBoris Cvek, Zdenek Dvorak
Mini Reviews in Medicinal Chemistry|August 31, 2012
Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cellsZdenek Skrott, Boris Cvek
Journal of Medicinal Chemistry|September 26, 2008
Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cellsBoris Cvek, Vesna Milacic, Jan Taraba, et al.
Pageof 2